University of California Davis
Davis, California, 95616, United States
NCT Number: NCT01838239
The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN) and in healthy subjects. The hypothesis is that measuring variation among individuals and changes in response to omega-3 fatty acids comprehensively by using metabolomics will help to identify those individuals who are responders and those who are non-responders to omega-3 fatty acids as an anti-inflammatory intervention.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Davis, California, 95616, United States
It is unclear how metabolomic profiles of individuals change in response to short-term intervention with omega-3 fatty acids. It is necessary to establish the means and standard deviations in the levels of omega-3 fatty acids and their related metabolites in healthy subjects and in different disease states in order to better understand the mechanisms related to lipid metabolism of metabolic diseases that are modified by omega-3 fatty acids. Specifically, the project will examine the metabolomic profiles of healthy controls and patients with immunoglobulin A nephropathy (IgAN) before and after an omega-3 fatty acid intervention. The IgAN patient samples were obtained from collaborators from a previously completed project. The healthy subjects were tested in a small pilot trial conducted at UC Davis as described below.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
Time frame: Baseline vs. 6 weeks
Plasma lipid metabolomic profile includes fatty acids within lipid classes, oxylipins, lipoprotein particle size and distribution
Time frame: Baseline vs. 6 weeks
Measurement of changes in gene expression in peripheral blood mononuclear cells
Time frame: Baseline vs. 6 weeks
Measurement of urinary oxylipins
University of California, Davis
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05834738
Autoimmune Diseases, Chronic Disease
Birmingham, Alabama, United States
View Trial DetailsNCT03719443
Autoimmune Diseases, Female Urogenital Diseases
Glendale, California, United States
View Trial DetailsNCT04287985
Autoimmune Diseases, Female Urogenital Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT05856760
Autoimmune Diseases, Female Urogenital Diseases
Birmingham, Alabama, United States
View Trial Details